Using Sodium Valproate in Children <2 Years of Age: Study in a District Hospital, Dinajpur, Bangladesh

Dr. Md. Mostafa Zaman^1, , Md. Saiful Islam², Sougata Mitra³, Md. Zakaria⁴ and Md. Tazul Islam⁵

¹Department of Paediatrics, Rangpur Medical College Hospital, Rangpur, Bangladesh

²Department of Radiology and Imaging, Rajshahi Medical College Hospital, Rajshahi, Bangladesh

³Department of Pharmacology and Therapeutics, Pabna Medical College, Pabna, Bangladesh

⁴Department of Paediatrics, Sunamgong Sadar Hospital, Sunamgong, Sylhet, Bangladesh

⁵Department of Paediatrics, 250 Bedded General Hospital, Jamalpur, Bangladesh

Cite this paper:
Dr. Md. Mostafa Zaman, Md. Saiful Islam, Sougata Mitra, Md. Zakaria and Md. Tazul Islam. Using Sodium Valproate in Children <2 Years of Age: Study in a District Hospital, Dinajpur, Bangladesh. American Journal of Medical Sciences and Medicine. 2021; 9(2):48-52. doi: 10.12691/ajmsm-9-2-3

Abstract

Introduction: Sodium valproate is proposed for addition to the Model List of Essential Medicines, for use in the management of epilepsy in children. This is effective in treating many seizure types, like a generalized tonic-clonic seizure, myoclonic seizure, absence seizure, in other epilepsy syndromes like an infantile spasm, Landau-Kleffner syndrome (LKS), etc. Aim of the study: This study aimed to observe the side effects caused by sodium valproate in children below 2 years of age. Methodology: An observational study was conducted in the Department of Paediatric M Abdur Rahim Medical College (MARMC), Dinajpur, Bangladesh, during the period of January 2019 to December 2019. Sixty (60) children < 2 the age of years with epilepsy were enrolled in this study. Enrollment was done after informed verbal consent from the mother or the attendant. Detail history was taken about demographic factors which include children’s age, age of onset of seizure, height, weight. Data were collected in a pre-designed questionnaire. The data was processed and analyzed by the application of SPSS version-22. Results: Male were dominated the gender distribution and were 54% and female were 46%. A maximum of 46% of patients was diagnosed with epilepsy between 6-12 months, Out of the total studied patients, the maximum 44% started sodium valproate ages between 7-12 months. Among the total studied patients 40% took 26-30mg/kg/day sodium valproate as their treatment regime. A total of 16% had anemia among the studied patients, whereas for the rest 84% of patients no other symptoms were found during their general examination. Among the total studied patients, the most dominating side effect of the patients was vomiting which resulted in 1/5^th (20%) of all side effects. The side effects of both hair loss and loss of appetite show the same result of 10% for each whereas, only 4% and 2% had abdominal pain and weight gain respectively. Conclusion: In this study vomiting was found as the most significant side effect which similar to other different studies also. These findings may be helpful for future researchers in further research. It was a single centered study with a small-sized sample.

Keywords:
epilepsy anti-epileptic drug sodium valproate

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Cecilie U. Johannessen, Svein I. Johannessen. Valproate: Past, Present, and Future. CNS Drug Rev. 2003; 9: 207-209.
[2]	Yogita Dawda, Niina Ezewuzie. Epilepsy pharmacological treatment and monitoring. Clinical pharmacist 2010; 2: 89-94.
[3]	http://lifeinthefastlane.com/book/critical-care-drugs/sodium-valproate (Accessed date: 02/02/2015).
[4]	Appleton RE, Farrell K, Applegarth DA, Dimmick JE, Wong LT, Davidson AG.The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci. 1990 May; 17 (2): 145-8.
[5]	Ebrahimi H, Shamsadini S, Eshkavari S S. Frequency of Sodium Valproate-Induced Hair Loss and Curly Hair. IJPT 2005; 4: 143-145.
[6]	Verity CM, Hosking G, Easter DJ. A multicenter comparative trail of sodium valproate and carbamazepine in Paediatric epilepsy. Dev Med Child Neurol, 1995; 37: 97-108.
[7]	Sodium valporate in childhood epilepsy: WHO. November 2006.
[8]	Chung B, Wat LC, Wong V. Febrile seizures in southern Chinese children: incidence and recurrent. Pediatr Neurol. 2006 Feb; 34 (2): 121-6.
[9]	Saravanan S. profile of children admitted with seizures in a tertiary care hospitals in south India. IOSR-JDMS. 2013; 11(4): 56-61.
[10]	J Egger and E M Brett. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed), 1981; 283(6291): 577-581.
[11]	Adhikari S, Sathian B, Koirala DP, Rao KS. Profile of children admitted with seizures in a tertiary care hospitals of Western Nepal. BMC Pediatr. 2013; 13: 43.
[12]	Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomised, parallel group study. Epilepsia, 2004; 45(9): 1049-1053.
[13]	Springview Cottage, More Hall Lane, Bolsterstone. Epilepsy in rural Ugandan children: seizure pattern, age of onset and associated findings. Afr Health Sci. 2010 Sep; 10(3): 218-225.
[14]	Ronald D Barr, Shirley A Copeland, Michelle L Stockwell, Neil Morris, John C Kelton. Valporoic acid and immune thrombocytopenia. Archives of Disease in Childhood, 1982; 57, 681-684.
[15]	Hjem M, de Silva LV, Seakins JW, Oberholzer VG, Rolles CJ. Evidence of inherited urea cycle defect in a case of fatal valproate toxicity.Br Med J 1986; 292: 23-24.
[16]	Honeycutt D, Callahan K, Rutledge L, Wans B, Heterozygotic ornithine transcarbamylase deficiency pre-senting as symptomatic hyperammonemia during initiation of valproate treatment. Neurology 1992; 42: 666-668.
[17]	Williams CA, Tiefenback S, McReynoldsJW. Valporic acid-induced hyperammonemia in mentaly retarded adults. Neurology 1984; 34: 550-553.
[18]	Paganini M, Zaccara G, Moroni F, Campostrini R, Bendoni L, Arnetoli G, Zappoli R. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia. The Drug Monit 1985; 7: 185-190.
[19]	Anderson GD, Children versus adults: pharmacokinetic and adverse-effects differences. Epilepsia. 2002; 43 Suppl 3: 53-9.
[20]	Ahmad E. Hamad, Mahmoud E. Fawzi. Valproate associated acute pancreatitis. Neurosciences 2000; 5 (3): 156-158.
[21]	Scott RA, Lhatoo SD, Sander JWA. The treatment of epilepsy in developing countries: where do wego from here? Bulletin of the WHO 2001; 79(4): 344-351.
[22]	Marson A,Tobias B, Sarah J, Marius W, Jamie N, Mauro J et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. PMC 2008; 134(3): 521-533.
[23]	Breum L, Astrup A, Gram L. Metabolic changes during treatment with valproate in human: Implications for weight gain. Metabolism 1992; 41: 666-670.